EAM
ACAD icon

EverPoint Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

EverPoint Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$4.33M Buy
+150,000
New +$3.97M 0.08% 267

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

EverPoint Asset Management's ACAD Position: Q4 2016 in Review

EverPoint Asset Management reduced its Acadia Pharmaceuticals (ACAD) stake by 69% in Q4 2016, selling an estimated $13.6M and leaving 235,000 shares worth $6.78M. The position accounts for 0.13% of the portfolio, ranked #194.

EverPoint Asset Management first reported a position in ACAD in Q2 2014 and has held it in 5 quarters since. The position peaked at $23.9M in Q3 2016. 225 funds tracked by Wall St. Rank hold ACAD as of Q4 2016.

  • EverPoint Asset Management held 235,000 shares of Acadia Pharmaceuticals worth $6.78M as of Q4 2016.
  • EverPoint Asset Management sold 515,000 Acadia Pharmaceuticals shares in Q4 2016, an estimated $13.6M.
  • Acadia Pharmaceuticals made up 0.13% of EverPoint Asset Management's portfolio in Q4 2016, its #194 holding.
  • EverPoint Asset Management first reported a position in Acadia Pharmaceuticals in Q2 2014 and has held it in 5 quarters since.
  • EverPoint Asset Management's Acadia Pharmaceuticals position peaked at $23.9M in Q3 2016.
  • 225 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2016.

Based on EverPoint Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.